Evidence map›Paper›PMID 36765653›Full record

ArticleCancers2023

Survival of Testicular Pure Teratoma vs. Mixed Germ Cell Tumor Patients in Primary Tumor Specimens across All Stages.

Cristina Cano Garcia, Francesco Barletta, Reha-Baris Incesu, Mattia Luca Piccinelli, Stefano Tappero, Andrea Panunzio, Zhe Tian, Fred Saad, Shahrokh F Shariat, Alessandro Antonelli and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Cristina Cano GarciaCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC H3A 2B4, Canada.ORCID 0000-0002-4829-0241
Francesco BarlettaCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC H3A 2B4, Canada.
Reha-Baris IncesuCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC H3A 2B4, Canada.
Mattia Luca PiccinelliCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC H3A 2B4, Canada.
Stefano TapperoCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC H3A 2B4, Canada.ORCID 0000-0001-9712-2685
Andrea PanunzioCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC H3A 2B4, Canada.ORCID 0000-0002-9756-4632
Zhe TianCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC H3A 2B4, Canada.
Fred SaadCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC H3A 2B4, Canada.ORCID 0000-0003-2986-5617
Shahrokh F ShariatDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria.
Alessandro AntonelliDepartment of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, 37126 Verona, Italy.ORCID 0000-0002-7455-8803
Carlo TerroneDepartment of Urology, IRCCS Policlinico San Martino, 16132 Genova, Italy.
Ottavio De CobelliDepartment of Urology, IEO European Institute of Oncology, IRCCS, 20141 Milan, Italy.
Markus GraefenMartini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, 20246 Hamburg, Germany.
Derya TilkiMartini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, 20246 Hamburg, Germany.ORCID 0000-0001-7033-1380
Alberto BrigantiUnit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, 20132 Milan, Italy.
Mike WenzelGoethe University Frankfurt, Department of Urology, University Hospital Frankfurt, 60590 Frankfurt, Germany.
Severine BanekGoethe University Frankfurt, Department of Urology, University Hospital Frankfurt, 60590 Frankfurt, Germany.
Luis A KluthGoethe University Frankfurt, Department of Urology, University Hospital Frankfurt, 60590 Frankfurt, Germany.
Felix K H ChunGoethe University Frankfurt, Department of Urology, University Hospital Frankfurt, 60590 Frankfurt, Germany.
Pierre I KarakiewiczCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC H3A 2B4, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We aimed to test for survival differences between testicular pure teratoma vs. mixed germ cell tumor (GCT) patients in a stage-specific fashion. Pure teratoma and mixed GCT in primary tumor specimens were identified within the Surveillance, Epidemiology, and End Results database (2004-2019). Kaplan-Meier curves depicted five-year overall survival (OS) and subsequently, cumulative incidence plots depicted cancer-specific mortality (CSM) and other-cause mortality (OCM) in a stage-specific fashion. Multivariable competing risks regression (CRR) models were used. Of 9049 patients, 299 (3%) had pure teratoma. In stage I, II and III, five-year OS rates differed between pure teratoma and mixed GCT (stage I: 91.6 vs. 97.2%,

Indexed as

non-seminomapure teratomaSEERsurvival analysestesticular cancer

Identifiers

PMID36765653
PMCPMC9913474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.